Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27
How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss
Wall Street Analysts Believe Replimune Group (REPL) Could Rally 26.8%: Here's is How to Trade
Leerink Partners Maintains Outperform on Replimune Group, Raises Price Target to $31
Is Replimune Group (REPL) Cheap Following Its Reduced Net Loss Results?
Replimune: 3 Key Takeaways for Long-Term Investors
Replimune Group, Inc. Q2 2027 Earnings Call Summary
Replimune (REPL) Q2 2027 Earnings Call Transcript
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript
Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group Q2 2027 Earnings Call Transcript
Replimune Group Q2 EPS $(0.54) Beats $(0.77) Estimate
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
Replimune Group (REPL) Stock Looks Rich After A 141% Run
Replimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes Clear
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Replimune Group Announces Commercial Availability Of TUDRIQEV In U.S. To Treat Unresectable Advanced Cutaneous Melanoma
Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.